Work

Entwicklung und Charakterisierung bispezifischer Antikörper-Derivate zur Immuntherapie CD19-positiver Leukämien und Lymphome

Year: 2008
Type: dissertation
Abstract: Bispecific antibodies are attractive agents for therapy of cancer and have been generated against different combinations of tumor antigens and trigger molecules on effector cells. Redirecting Natural Killer (NK) cells against leukemias and lymphomas is promising, as demonstrated by a bispecific single-chain fragment variable (bsscFv)against the tumor antigen CD19 and the trigger molecule CD16 (FcgRIII). However, monovalent targeting and almost equal equilibrium constants (KD) for binding to CD19 (KD = 42 nM) and to CD16 (KD = 56 nM) were considered unfavorable for tumor-site specific retention and cytotoxicity. Therefore, novel bispecific proteins with increased functional affinity for CD19 were designed. A bispecific bibody was generated by genetically fusing a CD19-directed fragment antigen binding (Fab) with a single-chain fragment variable (scFv) specific for CD16. By extension of this molecule with a CD19-directed scFv, a bispecific tribody was obtained, now being bivalent for CD19 and monovalent for CD16. The tribody displayed 3-fold greater avidity for CD19 (KD = 8 nM) than the bibody (KD = 23 nM)and equal affinity for CD16 (KD = 57 nM). Both the tribody and the bibody induced ADCC against human leukemia-derived cell lines and primary cells from tumor patients with human mononuclear cells (MNCs) as effectors. The tribody displayed half-maximum effective concentrations (EC50) of 55 pM, and promoted equal antibody-dependent cellular cytotoxicity (ADCC) at 6- and 12-fold lower concentrations than the bibody and the bsscFv, respectively. Based on these findings a novel format was designed, a scFv triple-body (sctb), consisting of one polypeptide chain with three scFvs connected in tandem. The two distal scFvs were specific for CD19, and the central scFv was directed against CD16. The sctb demonstrated 3-fold greater avidity for CD19 than the bsscFv (KD = 13 nM) and had equal affinity for CD16 (KD = 58 nM). The sctb induced ADCC against tumor cell lines and primary malignant cells at 10- to 40-fold lower EC50 than the bsscFv and therefore constituted a major improvement. In summary, converting CD19 and CD16 directed bispecific antibody-derivatives into bivalent targeting formats resulted in enhanced cytotoxicity. With EC50 in the low picomolar range, both the sctb and the tribody represent attractive candidates for further evaluation towards clinical studies.
Language: German
Subfield: Immunology
Open Access status: green
OpenAlex ID: W3154081031
Cites: 170
Cited by:
Related to: 9